GMAN Newsletter – October 2016

gman_logo_large

 

Cancer Moonshot Establishes Five Strategic Goals

On October 17th, US Vice President Joe Biden released his report from the Cancer Moonshot Task Force with recommendations on objectives for the initiative. We previously reported on the activities of the Task Force and the Blue Ribbon Panel in last month’s newsletter as both groups continued to gather information and generate recommendations. The October 17th report highlights five general strategic goals for the initiative with smaller subsets within each goal. Examples of the suggested goals include advancing data-sharing amongst researchers, capitalizing on new breakthroughs, delivering new treatments to patients more quickly and efficiently, improving diagnosis and prevention, and expanding overall access and care. Gain insight about the report HERE.

IMF Welcomes Robin Roland Levy as Senior Director of Public Policy and Advocacy

The IMF welcomes Robin Roland Levy as our new Senior Director of Public Policy and Advocacy. Robin will handle both US-based and international advocacy matters, including GMAN. Robin earned a Bachelor of Arts with a degree in Political Science with a Minor in Jewish Studies from The Richard Stockton College, and a Doctor of Law degree from George Mason University School of Law. She most recently worked at the Lymphoma Research Foundation as Director of Public Policy and Advocacy; prior to the LRF, Robin worked at the Anti-Defamation League as an Assistant Regional Director. Robin can be reached via her email at rlevy@myeloma.org. Please join us in welcoming Robin to our team!

Empliciti Approved in Japan and Israel

On October 3, 2016, Empliciti® (elotuzumab) was approved for use in Japan and Israel for patients who have received at least one prior therapy. It is indicated in combination with lenalidomide and dexamethasone and is the first and only immunostimulatory antibody for the treatment of multiple myeloma.

 

New MRD Testing Launched at 2nd IMF-EuroFlow Workshop

After years of dedicated research, a state-of-the-art myeloma test developed with the support of the IMF Black Swan Research Initiative® is on the brink of widespread availability. IMF Chairman Dr. Brian Durie reports from Spain, where an international workshop offered hands-on training and the latest news about this exciting new technology. Explore this topic at Dr. Durie’s blog.

 

FDA Grants Priority Review for Daratumumab in Relapsed Multiple Myeloma

On October 7, 2016, the FDA granted Priority Review to the supplemental Biologics License Application for the use of daratumumab in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. Priority Review is an FDA designation for drugs that treat a serious condition and may provide a significant improvement in safety or efficacy. Learn more HERE.

 

We Would Like to Thank Our Sponsors: Takeda Oncology, Celgene, Amgen, and Bristol-Myers Squibb

 

 

PageLines